Learn about enteropathic arthritis, a common extra-intestinal symptom of Crohn’s disease that affects the joints.

The European Commission (EC) has approved ustekinumab for the treatment of moderately to severely active Crohn’s disease in ...

Patients with Crohn’s disease had high Epstein-Barr virus seropositivity in the preclinical period and at diagnosis of inflammatory bowel disease, according to results of a cohort study of military ...

Silent Crohn’s disease may have little or no symptoms. It's important to monitor disease activity and treat the condition to ...

Crohn's disease belongs to a group of conditions known as inflammatory bowel diseases (IBD). This chronic condition causes inflammation in the digestive ...

Dr. Madeline Eckenrode is a med-peds physician serving patients in Birmingham, AL. These views are her own and do not reflect those of her employer. Names and circumstances have been changed to ...

The U.S. Food and Drug Administration has approved Johnson & Johnson's Tremfya (guselkumab) for adult patients with ...

Guselkumab is the first and only interleukin-23 inhibitor that offers both subcutaneous and intravenous induction options for ...

June 10, 2024 — Scientists have grown 'mini-guts' in the lab to help understand Crohn's disease, showing that 'switches' that modify DNA in gut cells play an important role in the disease ...

The FDA has approved Tremfya as the “first and only” interleukin-23 inhibitor that offers both IV and fully subcutaneous ...

The FDA has approved guselkumab (Tremfya) as the first IL-23 inhibitor offering both subcutaneous and intravenous induction ...